Carbohydrates (polyhydroxy aldehydes or ketones) are classified based on the degree of polymerization of constituent sugar residues:

• Monosaccharides: Simplest monomer units that cannot be hydrolyzed further.
  • By carbonyl group: Aldoses (e.g., D-glyceraldehyde, D-glucose) and Ketoses (e.g., Dihydroxyacetone, D-fructose).
  • By carbon chain length: Trioses (C₃H₆O₃), Tetroses (C₄H₈O₄), Pentoses (C₅H₁₀O₅, ribose), Hexoses (C₆H₁₂O₆, glucose, galactose), and Heptoses.
• Oligosaccharides: Yield 2 to 10 monosaccharide units upon hydrolysis.
  • Disaccharides: Maltose (α-1,4-glycosidic bond), Lactose (β-1,4-glycosidic bond), Sucrose (α-1,β-2 glycosidic bond).
  • Trisaccharides/Tetrasaccharides: Raffinose, Stachyose.
• Polysaccharides (Glycans): High-molecular-weight polymers composed of recurring monosaccharide chains (>10 units).
  • Homopolysaccharides: Single recurring monomer. E.g., Glycogen (α-1,4 chains with α-1,6 branches every 8–12 units), Starch (amylose α-1,4 and amylopectin α-1,6), and Cellulose (linear β-1,4-glucan).
  • Heteropolysaccharides: Repeated disaccharide units composed of different monomers. E.g., Glycosaminoglycans (GAGs) such as Hyaluronic acid, Chondroitin sulfate, and Heparin.

Monosaccharides spontaneously cyclize in aqueous solution through intramolecular hemiacetal/hemiketal ring closure:

• Fischer to Haworth Projection: Pyranose (6-membered ring) and Furanose (5-membered ring) configurations.
• Anomerism: Formation of a new asymmetric carbon (C1 in aldoses, C2 in ketoses) creating α and β anomers.
• Enantiomers: D- and L-isomers determined by the chiral carbon furthest from the primary carbonyl group.

• Primary Energy Substrate: D-Glucose is the obligate, preferential fuel for erythrocyte respiration and the central nervous system via glycolysis and the citric acid cycle (~4 kcal/g).
• Dynamic Energy Storage: Glycogen in mammalian hepatic and skeletal muscle stores energy for glycemic stability and contractile demand.
• Structural Scaffolding: Cellulose forms structural cell walls in plant systems; GAGs and proteoglycans form the shock-absorbing extracellular matrix (ECM) of mammalian cartilage and synovial fluids.
• Molecular Recognition & Cell Signaling: Oligosaccharide chains on glycoproteins and glycolipids act as cell surface markers, histocompatibility determinants (ABO blood groups), and receptor docking platforms.
• Nucleic Acid Backbone: D-Ribose and 2-deoxy-D-ribose form the invariant ribose-phosphate structural architecture of ATP, NAD⁺, RNA, and DNA.

Disaccharides (C₁₂H₂₂O₁₁) form via condensation reactions between the anomeric hydroxyl of one monosaccharide and a hydroxyl group of an adjacent sugar, releasing one H₂O molecule:

• Reducing Disaccharide: Retains a free, unbonded anomeric carbon (hemiacetal group) capable of mutarotation and reducing copper ions (Benedict's/Fehling's test).
• Non-Reducing Disaccharide: Both anomeric carbons are engaged together in the glycosidic bond, locking the rings against mutarotation or oxidation.

• Maltose (4-O-α-D-glucopyranosyl-D-glucopyranose):
  • Monomers & Linkage: α-D-Glucose + α/β-D-Glucose linked via an α-(1→4) glycosidic bond.
  • Properties: Reducing sugar; exhibits mutarotation; cleaved by intestinal maltase into two D-glucose molecules; forms petal-shaped osazone crystals.
• Lactose (4-O-β-D-galactopyranosyl-D-glucopyranose):
  • Monomers & Linkage: β-D-Galactose + α/β-D-Glucose linked via a β-(1→4) glycosidic bond.
  • Properties: Reducing sugar; hydrolyzed by brush-border lactase (deficiency produces clinical lactose intolerance); forms distinctive hedgehog / powder-puff shaped osazones.
• Sucrose (α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside):
  • Monomers & Linkage: α-D-Glucose + β-D-Fructose coupled via an α-1 → β-2 head-to-head glycosidic linkage.
  • Properties: Non-reducing sugar; negative Benedict's test; does not undergo mutarotation; upon acid/invertase hydrolysis, dextrorotatory sucrose ([α] = +66.5°) converts to levorotatory "invert sugar" mixture ([α] = -28.2°).

MALTOSE:   [α-D-Glc]-(C1) ---- O ---- (C4)-[D-Glc (Free C1 Anomer)]   ==> Reducing
LACTOSE:   [β-D-Gal]-(C1) ---- O ---- (C4)-[D-Glc (Free C1 Anomer)]   ==> Reducing
SUCROSE:   [α-D-Glc]-(C1) ---- O ---- (C2)-[β-D-Fru]                 ==> Non-Reducing
            

Vitamins A, D, E, and K are non-polar hydrophobic lipids requiring physiological lipid digestion pathways:

• Emulsification: Biliary bile salts and lecithin disperse fat-soluble vitamins into mixed micelles in the duodenal lumen.
• Intestinal Uptake: Micelles diffuse through the unstirred water layer; vitamins cross enterocyte apical membranes via passive diffusion or scavenger receptor class B type 1 (SR-BI) / CD36 transporters.
• Chylomicron Packaging: Re-esterified and packaged inside triacylglycerol-rich chylomicrons, then secreted into lymphatic lacteals and delivered to systemic blood via the thoracic duct.

• Vitamin A (Retinol & Carotenoids):
  • Transport: Cleared from chylomicron remnants by hepatocytes; released into plasma complexed with Retinol-Binding Protein (RBP) and transthyretin (TTR).
  • Storage: Stored primarily in hepatic Ito (stellate) cells as retinyl palmitate esters.
• Vitamin D (Cholecalciferol):
  • Transport: Bound to circulating Vitamin D-Binding Protein (VDBP). Undergoes hepatic 25-hydroxylation to 25-(OH)D₃ (calcidiol), and renal 1α-hydroxylation to active 1,25-(OH)₂D₃ (calcitriol).
  • Storage: Sequestered predominantly in white adipose tissue and skeletal muscle.
• Vitamin E (α-Tocopherol):
  • Transport: Specific hepatic cytosolic transfer protein (α-TTP) incorporates α-tocopherol into VLDL particles for systemic redistribution.
  • Storage: Stored non-specifically dissolved in body lipid depots and cell membrane bilayers.
• Vitamin K (Phylloquinone & Menaquinone):
  • Transport & Storage: Transported via chylomicrons and LDL; stored in hepatic reserves. Functions in hepatocytes via the Vitamin K-epoxide cycle to γ-carboxylate blood coagulation factors (II, VII, IX, X).

Malabsorption syndromes (celiac sprue, cystic fibrosis, biliary obstruction) impair bile micelle formation, resulting in systemic deficiency across all fat-soluble vitamins (night blindness, rickets/osteomalacia, coagulopathy).

Water-soluble vitamins (B-complex and Vitamin C) serve as indispensable metabolic catalysts and enzyme prosthetic groups, driving oxidative decarboxylation, hydride transfer, and transamination reactions in ATP synthesis.

• Vitamin B₁ (Thiamine) → Thiamine Pyrophosphate (TPP):

  Functions as a carbanion intermediate donor in the oxidative decarboxylation of α-keto acids. Essential catalytic cofactor for Pyruvate Dehydrogenase (PDH), α-Ketoglutarate Dehydrogenase (TCA cycle), and Transketolase (HMP shunt).

• Vitamin B₂ (Riboflavin) → FAD and FMN:

  Serve as two-electron / two-proton prosthetic groups. Drive Complex I (FMN) and Complex II (FAD-dependent Succinate Dehydrogenase) in the mitochondrial electron transport chain, and act as cofactors in fatty acyl-CoA dehydrogenation.

• Vitamin B₃ (Niacin) → NAD⁺ and NADP⁺:

  Reversible electron/hydride ion (H⁻) acceptors. NAD⁺ drives glycolytic GAPDH, PDH, and TCA cycle dehydrogenases; NADPH fuels anabolic biosynthetic pathways and maintains glutathione-mediated antioxidant defense.

• Vitamin B₅ (Pantothenic Acid) → Coenzyme A (CoA-SH):

  Features a reactive terminal thiol (-SH) group forming high-energy thioester bonds. Forms Acetyl-CoA and Succinyl-CoA, feeding carbon fragments into the TCA cycle and lipid metabolism.

• Vitamin B₆ (Pyridoxine) → Pyridoxal-5'-Phosphate (PLP):

  Forms Schiff base intermediates with amino acid α-amino groups, driving transamination (AST, ALT), deamination, and glycogen phosphorylase activity during amino acid and glycogen catabolism.

• Vitamin B₇ (Biotin):

  Covalently attached prosthetic group driving ATP-dependent carboxylation reactions, notably Pyruvate Carboxylase (gluconeogenesis) and Acetyl-CoA Carboxylase (lipogenesis).

The conversion of Pyruvate to Acetyl-CoA requires the concerted, coordinated action of five distinct vitamin-derived cofactors working in direct sequence: TPP (B₁), Lipoamide, CoA (B₅), FAD (B₂), and NAD⁺ (B₃).

Carcinogenesis is a sequential, evolutionary micro-process driven by cumulative somatic mutations across three defined stages: Initiation (irreversible DNA damage), Promotion (clonal expansion of pre-neoplastic cells), and Progression (acquisition of invasive metastatic phenotypes).

• Definition: Normal cellular genes promoting physiologic cell growth and division. A single allelic mutation confers a dominant, constitutively active oncogene phenotype.
• Activation Mechanisms:
  • Point Mutations: E.g., RAS codon 12 mutations abolish intrinsic GTPase activity, locking RAS in an active signaling state that drives continuous MAPK/ERK pathway proliferation.
  • Chromosomal Translocation: E.g., BCR-ABL Philadelphia chromosome t(9;22) producing a constitutive tyrosine kinase in CML; MYC translocation t(8;14) in Burkitt lymphoma.
  • Gene Amplification: E.g., HER2/neu amplification in breast carcinoma driving excessive epidermal growth factor signaling.

• Knudson's Two-Hit Hypothesis: Tumor suppressor gene inactivation generally requires loss-of-function events in both alleles (recessive at the cellular level).
• Key Classical Regulators:
  • RB1 (Retinoblastoma Protein): Master regulator of the G1/S cell cycle checkpoint. Hypophosphorylated RB binds and silences E2F transcription factors. Mutational loss of RB releases E2F unchecked, inducing continuous S-phase entry.
  • TP53 ("Guardian of the Genome"): Nuclear transcription factor induced by DNA double-strand breaks. Promotes cell cycle arrest via p21 (CDK inhibitor) induction to enable DNA repair, or activates Bax/PUMA to initiate apoptosis. Loss of p53 permits replication of damaged DNA and drives genomic instability.

Normal Epithelium  ---> Loss of APC (5q)             ---> Hyperproliferative Mucosa
                   ---> Early Adenoma Formation      ---> K-RAS Mutation (12p)
                   ---> Intermediate/Late Adenoma    ---> Loss of SMAD4/DCC (18q)
                   ---> Carcinoma in Situ            ---> Loss of TP53 (17p)
                   ---> Invasive Carcinoma           ---> Further Mutations / Telomerase
            

• Differentiation & Anaplasia:
  • Benign: Well-differentiated; closely resembles the normal tissue of origin with preserved cellular architecture.
  • Malignant: Displays anaplasia (lack of differentiation), pleomorphism (variation in cell size/shape), abnormal hyperchromatic nuclei, elevated nuclear-to-cytoplasmic (N:C) ratio (up to 1:1), and atypical tripolar mitotic figures.
• Rate of Growth:
  • Benign: Slow, progressive growth rate; may plateau or regress.
  • Malignant: Rapid, erratic growth driven by autocrine growth factor loops and evasion of programmed cell death (apoptosis).
• Local Invasion & Encapsulation:
  • Benign: Cohesive, expansive mass; enclosed by a fibrous pseudo-capsule; does not invade neighboring tissue planes.
  • Malignant: Infiltrative, destructive local invasion; lacks defined capsules; penetrates basement membranes and stromal boundaries.
• Metastatic Capacity:
  • Benign: Strictly absent; remains localized to its primary site.
  • Malignant: Possesses the biological capacity to seed distant anatomic sites (definitive hallmark of cancer).

• Lymphatic Spread: Primary pathway for carcinomas (epithelial origin). Tumor emboli invade lymphatic channels and track to regional sentinel lymph nodes (e.g., axillary nodes in breast carcinoma).
• Hematogenous Spread: Favored pathway for sarcomas (mesenchymal origin) and certain advanced carcinomas (e.g., renal cell carcinoma). Tumor cells invade thin-walled venules; venous drainage routes direct metastases to the liver (via portal flow) and lungs (via vena cava).
• Seeding of Body Cavities (Transcoelomic): Neoplastic cells penetrate into peritoneal, pleural, or pericardial spaces. E.g., ovarian carcinoma seeding the peritoneal cavity or forming Krukenberg tumors in gastric cancers.

Local invasion requires: (1) Downregulation of E-cadherin intercellular junctions → (2) Secretion of Matrix Metalloproteinases (MMPs) degrading the basement membrane → (3) Intravasation into blood/lymph vessels → (4) Evasion of immune NK cells via platelet aggregation → (5) Extravasation and colonization at secondary organ niches.

Excessive visceral adipose tissue drives sympathetic tone through central neurohormonal signaling:

• Hyperleptinemia & Leptin Resistance: While resistance develops against leptin's appetite-satiety effects, its action on hypothalamic pro-opiomelanocortin (POMC) neurons persists, driving continuous renal sympathetic nervous tone.
• Obstructive Sleep Apnea (OSA): Upper airway adiposity precipitates intermittent nocturnal hypoxemia and hypercapnia, stimulating peripheral chemoreceptors and sustaining high sympathetic vasoconstrictor output throughout the day.

• Adipose Autocrine RAAS Production: Visceral adipocytes directly synthesize and secrete angiotensinogen, angiotensin-converting enzyme (ACE), and Angiotensin II.
• Renal Tubular Sodium Reabsorption: Angiotensin II promotes systemic vasoconstriction and stimulates aldosterone secretion from the adrenal cortex, expanding extracellular fluid volume and elevating systemic vascular resistance.
• Physical Renal Compression: Accumulation of retroperitoneal and intrarenal adipose tissue inside the rigid renal capsule raises renal interstitial fluid hydrostatic pressure, slowing tubular flow and reinforcing pressure-natriuresis impairment.

• Impaired Nitric Oxide (NO) Bioavailability: Chronic release of pro-inflammatory adipokines (TNF-α, IL-6) and free fatty acids upregulates vascular NADPH oxidase, generating reactive oxygen species (ROS) that uncouple endothelial nitric oxide synthase (eNOS).
• Increased Peripheral Resistance: Diminished NO-dependent vasodilation paired with elevated endothelin-1 increases total peripheral resistance (TPR). Long-term remodeling causes arterial wall hypertrophy and medial stiffening, permanently elevating systolic and diastolic blood pressure.

Blood coagulation is a coordinated sequence of zymogen activations designed to convert soluble fibrinogen into a stable, cross-linked fibrin mesh:

• Extrinsic Pathway (Tissue Factor Pathway): Triggered by vascular injury exposing subendothelial Tissue Factor (TF), which complexes with Factor VIIa and Ca²⁺ to activate Factor X.
• Intrinsic Pathway (Contact Activation): Surface contact activates Factor XII → XIIa → XIa → IXa. Factor IXa, with Factor VIIIa, Ca²⁺, and phospholipid, forms the intrinsic tenase complex to activate Factor X.
• Common Pathway: Factor Xa pairs with Factor Va and Ca²⁺ on phospholipid surfaces to form the Prothrombinase complex, converting Prothrombin (Factor II) into active Thrombin (Factor IIa).
• Clot Stabilization: Thrombin cleaves fibrinopeptides A and B from soluble fibrinogen to yield fibrin monomers, while activating Factor XIII (Transglutaminase), which introduces covalent γ-glutamyl-ε-lysine isopeptide bonds between fibrin strands.

• Antithrombin III (AT-III): Circulating serine protease inhibitor that complexes with and inactivates thrombin, Factor Xa, and Factor IXa; its inhibitory kinetics are accelerated >1000-fold by endothelial heparin sulfate.
• Protein C / Protein S Pathway: Thrombin binding to endothelial Thrombomodulin redirects thrombin activity to cleave and activate Protein C (APC). With its cofactor Protein S, APC proteolytically cleaves and inactivates essential cofactors Factor Va and Factor VIIIa.
• Tissue Factor Pathway Inhibitor (TFPI): Directly inhibits Factor Xa, and then forms a quaternary inhibitory complex with TF-Factor VIIa.

Fibrinolysis dissolves established fibrin polymers to prevent vascular occlusion and restore lumen patency:

• Plasminogen Activation: Endothelial cells synthesize and release Tissue Plasminogen Activator (t-PA) and Urokinase (u-PA), which bind fibrin clots and convert inactive plasminogen to active Plasmin.
• Fibrin Degradation: Plasmin cleaves cross-linked fibrin into soluble Fibrin Degradation Products (FDPs) and D-Dimers.
• Inhibitory Control: Plasminogen Activator Inhibitor-1 (PAI-1) neutralizes free t-PA, while α₂-Antiplasmin rapidly inactivates circulating plasmin escaping the clot boundary, preventing systemic fibrinogenolysis.

Innate immunity provides rapid, non-specific protection present from birth, recognizing conserved pathogen-associated molecular patterns (PAMPs):

• Anatomical & Physiological Barriers: Stratified squamous epithelium of skin, acidic gastric juice (pH ~1.5–2.0), mucociliary escalator, and bactericidal enzymes (lysozyme in tears/saliva).
• Cellular Components: Neutrophils and Macrophages (phagocytosis and oxidative burst destruction), Natural Killer (NK) cells (perforin/granzyme-mediated killing of MHC-I deficient virus-infected/malignant cells), and Dendritic cells.
• Soluble Humor & Pattern Recognition: Toll-Like Receptors (TLRs) recognize microbial signatures; the Complement System (classical, alternative, lectin pathways) drives opsonization (C3b), chemotaxis (C5a), and pathogen lysis via the Membrane Attack Complex (MAC: C5b-9).

Adaptive immunity develops following antigen exposure, featuring high specificity, clonal expansion, and immunological memory:

• Cell-Mediated Immunity (T Lymphocytes):
  • CD4⁺ Helper T Cells (T_H): Recognize exogenous peptide antigens presented on MHC Class II molecules of APCs. Differentiate into T_H1 (IL-2, IFN-γ activating macrophages and CTLs) or T_H2 (IL-4, IL-5 driving B-cell class switching).
  • CD8⁺ Cytotoxic T Lymphocytes (CTLs): Recognize endogenous viral/mutant peptides presented on MHC Class I molecules, releasing perforins and granzymes to induce target cell apoptosis.
• Humoral Immunity (B Lymphocytes):

  B-cell receptors (membrane IgM/IgD) bind native conformational antigens. Upon CD4⁺ T-cell co-stimulation (CD40-CD40L interaction), B cells proliferate and differentiate into memory B cells and antibody-secreting plasma cells producing five immunoglobulin classes (IgM, IgG, IgA, IgE, IgD).

+-----------------------------------------------------------------------------------+
|                        TOTAL HUMAN IMMUNE ARCHITECTURE                            |
+-------------------------------------------------+---------------------------------+
|               INNATE IMMUNITY                   |        ADAPTIVE IMMUNITY        |
|  - Speed: Immediate (hours)                     |  - Speed: Delayed (days-weeks)  |
|  - Specificity: Broad, invariant (PAMPs)        |  - Specificity: High (epitopes) |
|  - Memory: None                                 |  - Memory: Robust and durable   |
|  - Elements: Skin, Lysozyme, Phagocytes,        |  - Elements: T & B Lymphocytes, |
|    NK cells, Complement cascade                 |    MHCs, Clonal Antibodies      |
+-------------------------------------------------+---------------------------------+
            

Enzyme-Linked Immunosorbent Assay (ELISA) couples the high specificity of antigen-antibody affinity binding with the high catalytic amplification of enzymes to quantify target antigens or circulating antibodies:

• Solid Phase Immobilization: Polystyrene 96-well microtiter plates passively bind proteins via hydrophobic/electrostatic interactions.
• Blocking Phase: Unoccupied surface adsorption sites are saturated with non-reactive proteins (e.g., 1–3% Bovine Serum Albumin or casein) to prevent non-specific background binding.
• Enzymatic Reaction & Signal Generation: Reporter enzymes (Horseradish Peroxidase - HRP, or Alkaline Phosphatase - ALP) oxidize chromogenic substrates (e.g., TMB or pNPP). Oxidation of TMB yields a soluble blue diimine product, shifting to bright yellow upon addition of sulfuric acid (H₂SO₄ stop solution).

• Direct ELISA: Target antigen is immobilized on plate wells → Enzyme-conjugated primary antibody is added directly → Washing → Substrate addition. Advantage: Fast; Disadvantage: Weak amplification and risk of antibody inactivation during labeling.
• Indirect ELISA: Antigen is immobilized → Primary clinical antibody (e.g., patient serum IgG) binds to antigen → Washing → Enzyme-conjugated secondary anti-human IgG antibody binds to primary antibody Fc region → Substrate addition. Application: HIV screening, COVID-19 serology.
• Sandwich ELISA: High-affinity capture antibody is coated onto the well → Sample containing multi-epitope antigen is introduced and captured → Washing → Enzyme-linked detection antibody targeting a distinct epitope is added ("sandwiching" the antigen) → Substrate addition. Application: Cytokine profiling, cardiac troponin, viral capsids.
• Competitive ELISA: Sample antigen competes with an enzyme-labeled reference antigen for a limited number of immobilized antibody binding sites. Key Readout: Signal intensity is inversely proportional to the concentration of target analyte in the sample.

Absorbance (Optical Density, OD) is read at specific wavelengths (e.g., 450 nm for acidified TMB) using an automated microplate spectrophotometer. Sample concentrations are determined by interpolating OD values onto standard calibration curves prepared with known analyte dilutions.